blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1732903

EP1732903 - TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.12.2009
Database last updated on 28.09.2024
Most recent event   Tooltip07.10.2011Lapse of the patent in a contracting state
New state(s): CY, TR		published on 09.11.2011  [2011/45]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2009/08]
Former [2006/51]For all designated states
AstraZeneca AB
S-151 85 Södertälje / SE
Inventor(s)01 / ERIKSSON, Anders
AstraZeneca R & D Lund
S-221 87 Lund / SE
02 / LEPISTÖ, Matti
AstraZeneca R & D Lund
S-221 87 Lund / SE
 [2006/51]
Application number, filing date05722275.429.03.2005
[2006/51]
WO2005SE00448
Priority number, dateSE2004000085030.03.2004         Original published format: SE 0400850
[2006/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2005095362
Date:13.10.2005
Language:EN
[2005/41]
Type: A1 Application with search report 
No.:EP1732903
Date:20.12.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 13.10.2005 takes the place of the publication of the European patent application.
[2006/51]
Type: B1 Patent specification 
No.:EP1732903
Date:18.02.2009
Language:EN
[2009/08]
Search report(s)International search report - published on:SE13.10.2005
ClassificationIPC:C07D249/08, A61K31/4196, A61P11/06, A61P11/00, C07D213/36, C07C311/50
[2006/51]
CPC:
C07D249/12 (EP,US); A61P11/00 (EP); A61P11/06 (EP);
A61P43/00 (EP); C07D401/12 (EP,US); C07D401/14 (EP,US);
C07D417/14 (EP,US); C07D491/10 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/51]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
LVNot yet paid
MKNot yet paid
YUNot yet paid
TitleGerman:TRIAZOLONDERIVATE ALS MMP-INHIBITOREN ZUR BEHANDLUNG VON ASTHMA UND COPD[2006/51]
English:TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD[2006/51]
French:DERIVES DE LA TRIAZOLONE UTILISES COMME INHIBITEURS DE LA MMP DANS LE TRAITEMENT DE L'ASTHME ET DE LA BPCO[2006/51]
Entry into regional phase30.10.2006National basic fee paid 
30.10.2006Designation fee(s) paid 
30.10.2006Examination fee paid 
Examination procedure30.10.2006Examination requested  [2006/51]
21.04.2008Despatch of a communication from the examining division (Time limit: M04)
08.08.2008Reply to a communication from the examining division
29.09.2008Communication of intention to grant the patent
23.12.2008Fee for grant paid
23.12.2008Fee for publishing/printing paid
Opposition(s)19.11.2009No opposition filed within time limit [2010/04]
Fees paidRenewal fee
02.04.2007Renewal fee patent year 03
28.03.2008Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT18.02.2009
BE18.02.2009
CY18.02.2009
CZ18.02.2009
DK18.02.2009
EE18.02.2009
FI18.02.2009
LT18.02.2009
NL18.02.2009
PL18.02.2009
RO18.02.2009
SI18.02.2009
SK18.02.2009
TR18.02.2009
IE29.03.2009
LU29.03.2009
MC31.03.2009
BG18.05.2009
GR19.05.2009
IS18.06.2009
PT27.07.2009
HU19.08.2009
[2011/44]
Former [2011/32]AT18.02.2009
BE18.02.2009
CZ18.02.2009
DK18.02.2009
EE18.02.2009
FI18.02.2009
LT18.02.2009
NL18.02.2009
PL18.02.2009
RO18.02.2009
SI18.02.2009
SK18.02.2009
IE29.03.2009
LU29.03.2009
MC31.03.2009
BG18.05.2009
GR19.05.2009
IS18.06.2009
PT27.07.2009
HU19.08.2009
Former [2011/22]AT18.02.2009
BE18.02.2009
CZ18.02.2009
DK18.02.2009
EE18.02.2009
FI18.02.2009
LT18.02.2009
NL18.02.2009
PL18.02.2009
RO18.02.2009
SI18.02.2009
SK18.02.2009
IE29.03.2009
LU29.03.2009
MC31.03.2009
BG18.05.2009
GR19.05.2009
IS18.06.2009
PT27.07.2009
Former [2010/52]AT18.02.2009
BE18.02.2009
CZ18.02.2009
DK18.02.2009
EE18.02.2009
FI18.02.2009
LT18.02.2009
NL18.02.2009
PL18.02.2009
RO18.02.2009
SI18.02.2009
SK18.02.2009
IE29.03.2009
MC31.03.2009
BG18.05.2009
GR19.05.2009
IS18.06.2009
PT27.07.2009
Former [2010/12]AT18.02.2009
BE18.02.2009
CZ18.02.2009
DK18.02.2009
EE18.02.2009
FI18.02.2009
LT18.02.2009
NL18.02.2009
PL18.02.2009
RO18.02.2009
SI18.02.2009
SK18.02.2009
IE29.03.2009
MC31.03.2009
BG18.05.2009
IS18.06.2009
PT27.07.2009
Former [2010/07]AT18.02.2009
BE18.02.2009
CZ18.02.2009
DK18.02.2009
EE18.02.2009
FI18.02.2009
LT18.02.2009
NL18.02.2009
PL18.02.2009
RO18.02.2009
SI18.02.2009
SK18.02.2009
IE29.03.2009
MC31.03.2009
IS18.06.2009
PT27.07.2009
Former [2009/52]AT18.02.2009
BE18.02.2009
CZ18.02.2009
DK18.02.2009
EE18.02.2009
FI18.02.2009
LT18.02.2009
NL18.02.2009
PL18.02.2009
RO18.02.2009
SI18.02.2009
SK18.02.2009
MC31.03.2009
IS18.06.2009
PT27.07.2009
Former [2009/48]AT18.02.2009
BE18.02.2009
DK18.02.2009
EE18.02.2009
FI18.02.2009
LT18.02.2009
NL18.02.2009
PL18.02.2009
SI18.02.2009
MC31.03.2009
IS18.06.2009
Cited inInternational search[A]EP0726258  (BAYER AG [DE]);
 [A]WO0074679  (MERCK & CO INC [US], et al);
 [A]EP1110958  (UCB SA [BE]);
 [A]WO0146167  (UCB SA [BE], et al);
 [A]WO03078376  (SCHERING CORP [US]);
 [A]WO03089429  (MERCK & CO INC [US], et al);
 [A]WO03092690  (PROCTER & GAMBLE [US]);
 [A]  - XU Y. ET AL., "Desing and synthesis of a potent and selective triazolone-base", J.MED.CHEM., (2003), vol. 46, pages 5121 - 5124, XP002299289

DOI:   http://dx.doi.org/10.1021/jm034173l
 [A]  - ROMINE J. ET AL., "4,5-diphenyltriazol-3-ones: openers of large-conductante Ca2+activated potassium (maxi-K) channels.", J.MED.CHEM., (2002), vol. 45, pages 2942 - 2952, XP002989030

DOI:   http://dx.doi.org/10.1021/jm010569q
Examination   - BECKETT R.P.; WHITTAKER M., "Matrix metalloproteinase inhibitors 1998", EXP. OPIN. THER. PATENTS, ASHLEY PUBLICATIONS, GB, (19980101), vol. 8, no. 3, pages 259 - 282, XP002430631

DOI:   http://dx.doi.org/10.1517/13543776.8.3.259
    - WHITTAKER M. ET AL, "DESIGN AND THERAPEUTIC APPLICATION OF MATRIX METALLOPROTEINASE INHIBITORS", CHEM. REV., ACS, WASHINGTON, DC, US, (19990901), vol. 99, no. 9, pages 2735 - 2776, XP000852443

DOI:   http://dx.doi.org/10.1021/cr9804543
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.